Allogene Therapeutics, Inc. (ALLO) Financial Statements (2024 and earlier)

Company Profile

Business Address 210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:544,500514,000576,500637,300686,100733,100
Cash and cash equivalents154,758109,93161,90474,35796,04184,514
Short-term investments337,204361,293455,416477,872394,451364,536
Other undisclosed cash, cash equivalents, and short-term investments52,53842,77659,18085,071195,608284,050
Other undisclosed current assets(42,399)(32,535)(47,676)(68,239)(173,072)(263,356)
Total current assets:502,101481,465528,824569,061513,028469,744
Noncurrent Assets
Operating lease, right-of-use asset80,31481,96483,59285,24586,83757,057
Property, plant and equipment106,386109,849112,839114,442117,216120,200
Long-term investments and receivables62,49653,91271,96899,154211,333298,297
Long-term investments62,49653,91271,96899,154211,333298,297
Restricted cash and investments10,29210,29210,29210,29210,29210,292
Other noncurrent assets9,3829,3899,5649,3788,9389,042
Total noncurrent assets:268,870265,406288,255318,511434,616494,888
TOTAL ASSETS:770,971746,871817,079887,572947,644964,632
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,22914,68831,82511,0459,7138,708
Accounts payable10,22914,68813,89011,0459,7138,708
Accrued liabilities   17,935   
Deferred revenue229273885889836406
Deferred compensation liability1,5001,9001,9001,9001,9002,300
Other liabilities   2,118   
Other undisclosed current liabilities42,76342,72417,79035,03832,46025,463
Total current liabilities:54,72159,58554,51848,87244,90936,877
Noncurrent Liabilities
Long-term debt and lease obligation:    96,70698,23269,035
Liabilities, other than long-term debt93,34495,02496,6912,0332,5543,490
Other liabilities1,5231,5101,5692,0332,5543,490
Operating lease, liability91,82193,51495,12296,70698,23269,035
Total noncurrent liabilities:93,34495,02496,69198,739100,78672,525
Total liabilities:148,065154,609151,209147,611145,695109,402
Equity
Equity, attributable to parent622,906592,262665,870739,961801,949855,230
Common stock167146144144144143
Additional paid in capital2,039,2631,932,7341,911,6321,893,9081,871,2621,847,534
Accumulated other comprehensive loss(3,851)(5,934)(9,926)(12,958)(11,472)(9,249)
Accumulated deficit(1,412,673)(1,334,684)(1,235,980)(1,141,133)(1,057,985)(983,198)
Total equity:622,906592,262665,870739,961801,949855,230
TOTAL LIABILITIES AND EQUITY:770,971746,871817,079887,572947,644964,632

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues445247498661
Gross profit:445247498661
Operating expenses(80,562)(99,122)(96,421)(82,538)(76,680)(80,053)
Operating loss:(80,518)(99,070)(96,374)(82,489)(76,594)(79,992)
Nonoperating income (expense)2,5293661,527(659)1,807142
Other nonoperating income (expense)(1,249)2,059(1,230)(1,661)1,492492
Loss from continuing operations:(77,989)(98,704)(94,847)(83,148)(74,787)(79,850)
Loss before gain (loss) on sale of properties:(83,148)(74,787)(79,850)
Net loss available to common stockholders, diluted:(77,989)(98,704)(94,847)(83,148)(74,787)(79,850)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(77,989)(98,704)(94,847)(83,148)(74,787)(79,850)
Comprehensive loss:(77,989)(98,704)(94,847)(83,148)(74,787)(79,850)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2,0833,9923,032(1,486)(2,223)(6,682)
Comprehensive loss, net of tax, attributable to parent:(75,906)(94,712)(91,815)(84,634)(77,010)(86,532)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: